Latest articles
No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Financial Histories
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
Overview
GNFT.PADay performance
| GNFT.PA | |
|---|---|
| Price | 2.99 |
| Change Pct | -0.50 |
| Change Abs | -0.02 |
| Market Cap | 149.0 million |
| Eps | -0.65 |
| Pe Ratio | -4.60 |
| Outstanding Shares | 49.8 million |
| Volume | 46444 |
| Avg Volume | 238489 |
| Industry | Biotechnology |
| Sector Name | Health Care |
| Country Short Name | FR |
| Announcement Earnings | 2023-11-09 10:59:00+00:00 |
Dividends
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Risk Profiles
Please sign up and become a member to view all risk profiles.
Peers
DBV.PA
NANO.PA
ALCLS.PA
3 Login now
Focus
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
GNFT.PA
Company descriptions
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA);